Please assess the completion status of the following clinical trial:

Trial Title: Multiple Ascending Dose (MDX1105-01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1~* The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pancreatic cancer and breastcancer~* Must have measurable disease~Exclusion Criteria:~* Prior therapy with an anti-PD 1, anti-PDL 1, or anti-Cytotoxic T-Lymphocyte Antigen 4 antibody (or any other agents that target T-cell co-stimulation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-PDL-1 antibody (Arm 1) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 2) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 3) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 4) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)
- Anti-PDL-1 antibody (Arm 5) (Type: EXPERIMENTAL): BMS-936559 (MDX-1105)

Based on this trial design, predict the completion outcome and termination type (if applicable).